Recombinant gastric lipase - Meristem

Drug Profile

Recombinant gastric lipase - Meristem

Alternative Names: Merispase®; Recombinant gastric lipase

Latest Information Update: 03 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meristem Therapeutics
  • Class Carboxylic ester hydrolases
  • Mechanism of Action Lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders

Highest Development Phases

  • Discontinued Pancreatic disorders

Most Recent Events

  • 25 Feb 2005 Profile reviewed with information presented at the 3rd Annual BioPartnering North America (BPN-2005)
  • 25 Feb 2005 Recombinant gastric lipase is available for licensing (http://www.meristem-therapeutics.com)
  • 21 Jun 2004 Phase-II clinical trials in Pancreatic disorders in Europe (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top